Zura Bio (NASDAQ:ZURA – Get Free Report) and Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.
Profitability
This table compares Zura Bio and Dianthus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zura Bio | N/A | -56.13% | -50.15% |
| Dianthus Therapeutics | -10,096.95% | -22.53% | -21.55% |
Valuation and Earnings
This table compares Zura Bio and Dianthus Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zura Bio | N/A | N/A | -$99.35 million | ($1.13) | -5.12 |
| Dianthus Therapeutics | $2.04 million | 3,026.39 | -$162.34 million | ($4.15) | -27.21 |
Zura Bio has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Zura Bio has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Zura Bio and Dianthus Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zura Bio | 1 | 0 | 5 | 1 | 2.86 |
| Dianthus Therapeutics | 1 | 0 | 12 | 1 | 2.93 |
Zura Bio currently has a consensus target price of $17.00, indicating a potential upside of 193.61%. Dianthus Therapeutics has a consensus target price of $124.27, indicating a potential upside of 10.05%. Given Zura Bio’s higher probable upside, research analysts plainly believe Zura Bio is more favorable than Dianthus Therapeutics.
Institutional & Insider Ownership
61.1% of Zura Bio shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 12.4% of Zura Bio shares are held by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Zura Bio beats Dianthus Therapeutics on 7 of the 13 factors compared between the two stocks.
About Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.
